Jacobi Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Jacobi Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20	Closed	–	–	442
2021 Q3	$0	Hold	20	–	–	﹤0.01%	1434
2021 Q2	$1K	Hold	20	–	–	﹤0.01%	1302
2021 Q1	$2K	Hold	20	–	–	﹤0.01%	1227
2020 Q4	$2K	Hold	20	–	–	﹤0.01%	1140
2020 Q3	$2K	Hold	20	–	–	﹤0.01%	1069
2020 Q2	$4K	Hold	20	–	–	﹤0.01%	938
2020 Q1	$2K	Hold	20	–	–	﹤0.01%	938
2019 Q4	$2K	Hold	20	–	–	﹤0.01%	945
2019 Q3	$1K	Hold	20	–	–	﹤0.01%	977
2019 Q2	$2K	Hold	20	–	–	﹤0.01%	916
2019 Q1	$1K	Hold	20	–	–	﹤0.01%	917
2018 Q4	$1K	Hold	20	–	–	﹤0.01%	888
2018 Q3	$1K	Hold	20	–	–	﹤0.01%	924
2018 Q2	$1K	Hold	20	–	–	﹤0.01%	955
2018 Q1	$1K	Hold	20	–	–	﹤0.01%	919
2017 Q4	$1K	Hold	20	–	–	﹤0.01%	877
2017 Q3	$1K	Hold	20	–	–	﹤0.01%	863
2017 Q2	$1K	Hold	20	–	–	﹤0.01%	788
2017 Q1	$1K	Hold	20	–	–	﹤0.01%	662
2016 Q4	$1K	Hold	20	–	–	﹤0.01%	580
2016 Q3	$1K	Buy	+20	New	+$759	﹤0.01%	681

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobi Capital Management's ADVM Position: Q4 2021 in Review

Jacobi Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 20 shares.

Jacobi Capital Management first reported a position in ADVM in Q3 2016 and held it in 21 quarters. The position peaked at $4K in Q2 2020. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

Jacobi Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 20 Adverum Biotechnologies shares in Q4 2021.
Jacobi Capital Management first reported a position in Adverum Biotechnologies in Q3 2016 and held it in 21 quarters.
Jacobi Capital Management's Adverum Biotechnologies position peaked at $4K in Q2 2020.
98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.